Abstract Tumour vasculature targeting has been a very active area of cancer drug discovery over the last decade. Growth of solid tumours beyond a certain point requires a sufficient blood supply in order for them to develop and metastasise. While novel anti-angiogenic and vascular disrupting agents represent an important contribution to the armoury of anti-cancer agents they nevertheless usually require combination with standard cytotoxic therapy in order to demonstrate positive clinical outcomes. In line with this consensus, a new concept has arisen, namely the design of functional hybrids where at least one component of the design targets a tumour angiogenic/vasculature pathway. This review will outline examples of such hybrid/ conjugate-based approaches. Emphasis will be placed on their preclinical evaluation with particular focus on the RGD/NGR-conjugates, heparin-related hybrids and antibody-drug conjugates. In conclusion, the benefits and shortcomings of hybrids under development will be discussed in the context of future directions and applications.
results in alignment of endothelial cells into capillary tubes (vasculogenesis). Physiologically, this process takes place during embryogenesis, and the female reproductive cycle, as well as in wound healing. During tumour angiogenesis, the ''angiogenic switch'' is turned on causing the normally quiescent vasculature to constantly sprout new vessels, thus facilitating tumour growth [1, 2] . As evident from earlier in vivo work in rabbits with implanted tumours and nontumour tissue in non-vascularised cornea, tumour growth was shown to be angiogenesis-dependent. Tumour tissue was able to grow once newly formed vasculature was developed, whereas non-tumour tissue did not attract new blood vessels [3] . Angiogenesis is a complex process which involves a number of steps including the production and release of angiogenic factors (upon activation by hypoxia or genetic mutations) [4] [5] [6] , and the binding of these factors to vascular endothelial cell receptors, causing activation and cell proliferation. Extracellular metalloproteinases mediate many of the changes in the microenvironment by degrading the extracellular matrix (ECM) in front of the proliferating endothelial cells [7] . Endothelial cells then subsequently migrate towards the tumour tissue where they align to form new blood vessels and connect to create a loop that allows the blood to circulate. Specialised muscle cells (e.g. smooth muscle cells and pericytes) stabilise the vessel tubes providing structural support [8] .
Angiogenic regulators
Many endogenous molecules are involved in the control of angiogenesis and several of these have been studied for potential therapeutic applications. Pro-angiogenic regulators include vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs), platelet-derived growth factors (PDGFs), epidermal growth factors (EGFs) and their associated tyrosine kinase receptors, VEGFRs, FGFRs, PDGFRs and EGFRs and matrix metalloproteinases (MMPs).
Endogenous angiogenesis inhibitors include thrombospondin-1 (TSP-1), angiostatin, endostatin, tumstatin and canstatin. TSP-1 counteracts pro-angiogenic stimuli by evoking suppressive signals through activation of endothelial cell receptors [9] . Angiostatin and endostatin are produced in the tumour stroma through the action of proteinases which are induced as part of the angiogenic cascade [10] . Angiostatin (an internal fragment of plasminogen containing at least three of the kringles of plasminogen) was shown to be inversely correlated with VEGF and inhibited endothelial cell migration, tube formation and aortic ring sprouts [11] . In an in vivo assay, angiostatin was found to maintain metastases in a dormant state when administered exogenously [12] and was associated with longer patient survival [13] . A Phase II trial using recombinant human angiostatin (hAngiostatin) in combination with paclitaxel and carboplatin resulted in a high disease control rate in patients with advanced NSCLC [14] . While angiostatin has shown clinical potential, a significant disadvantage with this agent is its short half-life (*15 min), leading to a need for continuous administration [15, 16] .
Endostatin (C-terminal fragment of collagen XVIII) has also shown anti-angiogenic activity in vitro by suppressing VEGF-induced tyrosine phosphorylation of VEGFR-1/2, as well as overall VEGFR-2 expression and the activation of ERK, p38, mitogen activated protein kinase (MAPK) and AKT in HUVECs [17] . Treatment with endostatin resulted in inhibition of proliferation, migration, and tube formation of endothelial cells, resulting in inhibition of angiogenesis and tumour growth [18, 19] . Endostatin inhibited primary tumour growth of non-small cell lung cancer (NSCLC), Lewis lung carcinoma and B16F10 melanoma, and maintained metastasis in a dormant state, without exhibiting apparent side effects [20] [21] [22] [23] . In China, endostatin (Endostar TM ) has been approved for the treatment of NSCLC [24] . The urine levels of endostatin and VEGF were proven to be clinically useful in the diagnosis of bladder cancer, and endostatin but not VEGF, showed to be a supplementary prognostic marker for predicting tumour progression [25] . In addition, high levels of endostatin were associated with poor survival of patients with advancedstage nasopharyngeal carcinoma [26] . Although the mechanism associated with high levels of endostatin and poor clinical outcome is unclear, the elevation of endostatin in particular cancer types, such as the nasopharyngeal carcinoma, might be a result of increased tumour angiogenesis, which reflects in tumour burden. In addition, increased serum endostatin concentration may indicate unidentified micro-metastatic disease.
Tumstatin (a3 chain type IV collagen NC1 domain a3(IV)NC1) mediates its anti-angiogenic activity by interaction with the a m b 3 integrin in an RGD (arginineglycine-aspartic acid)-independent manner [27] and inhibits protein synthesis specifically in endothelial cells [28] . Tumstatin's therapeutic potential was studied in a number of tumour models, including human prostate and renal cell carcinoma (RCC) [29, 30] , as well as laryngeal squamous carcinoma xenografts [31] . Studies conducted by Luo et al. [32] demonstrated that tumstatin-mRNA expression level correlates with prognosis in NSCLC, suggesting that tumstatin-mRNA may be a potential marker of a favourable prognosis in NSCLC. It was identified that a peptide composed of residues 45-132 of a3(IV)NC1fragment was sufficient to inhibit in vitro and in vivo angiogenesis through induction of apoptosis [27] . Thus, further tumstatin-related peptides were synthesised and demonstrated anti-angiogenic and anti-tumour effects [33] [34] [35] .
Canstatin (NC1 domain of the a2 chain of type IV collagen) was shown to inhibit endothelial cell migration, capillary tube formation and suppression of tumour growth in prostate, RCC, squamous cell carcinoma (SCC), pancreatic and breast cancer xenograft models [36] [37] [38] [39] . In addition, canstatin inhibited AKT activation, induced FASdependent apoptosis in endothelial cells [40] and inhibited angiogenesis and lymphangiogenesis via suppression of the integrin-dependent FAK signalling (induced by angiopoietin-1/Tie-2 and/or VEGFR-3) [41] . Xing et al. [42] demonstrated that the anti-tumour activity of exogenous and endogenous canstatin was greater than either treatment alone in colorectal cancer cells.
The expression of these factors can be induced by environmental stress including glucose deprivation, formation of reactive oxygen species, cellular acidosis and iron deficiency, by the loss of the function of tumoursuppressor genes or by the activation of oncogenes [43] [44] [45] . Simple changes in the relative balance of inducers and inhibitors of angiogenesis can activate the ''angiogenic switch''. Furthermore, newly characterised ligands of signal-transducing receptors which are displayed by endothelial cells include notch, neuropilin, robo and ephrin Eph-A/B receptors. These pathways have been shown to be associated with developmental and tumour-driven angiogenesis, demonstrating the complexity of endothelial cell regulation [46] [47] [48] [49] .
Tumour vasculature
Morphologically, anatomically and functionally, tumour vasculature differs from the normal vasculature and is associated with an abnormally increased rate of angiogenesis. Particularly so in undeveloped tumour blood vessels which are often distinguished by their abnormal characteristics including fragility, chaotic arrangements, imperfect vessel walls due to discontinuous endothelial cell lining and weak investiture with vascular smooth muscle cells. Additionally, there are poor connections between pericytes and endothelial cells which themselves are usually irregularly shaped, forming an uneven luminal layer with loose interconnections and focal intercellular openings [50] [51] [52] [53] . Tumour blood vessels have an irregular, structurally abnormal basement membrane [54, 55] , uneven diameter and very long distance between branching points, which results in a chaotic vascular network with complex branching patterns and lack of hierarchy [56] [57] [58] . These characteristics of the newly developed tumour vasculature allows for macromolecule diffusion, aid the metastatic process by facilitating the tumour cells into the bloodstream and accumulates fibrin in the ECM, therefore favouring angiogenesis. The histological grade and malignant potential of the tumour normally correlates with the degree of blood vessel leakiness [59] .
Why target the tumour vasculature?
The ability to selectively target established tumour vasculature is a very appealing strategy for the treatment of cancer, which allows rapid vascular shutdown, leading to secondary tumour cell death. The differences between tumour and normal blood vessels described earlier might be the reason why tumour vasculature is more susceptible to vascular disrupting agents (VDAs) than normal vasculature. These types of agents have several advantages over conventional chemotherapeutic agents as the therapy is effective in the majority of solid tumours, regardless of histological sub type. Killing of relatively few vascular endothelial cells is likely to result in the death of a large area of tumour via widespread central necrosis whereas direct targeting of tumour cells require all cells to be killed in order for the therapy to be effective. VDAs also have the ability to avoid undesirable acquired drug resistance as they target normal vascular endothelial cells which are considered more genetically stable than tumour cells. An additional advantage is that drug delivery to cellular targets lining blood vessels is easier to achieve compared with targets in the tumour area distant from capillaries [60] .
Intuitively, there are two different approaches that may be used to cause disruption of the blood supply to the tumour: Targeting tumour angiogenesis or the established tumour vasculature. Clinically, the most promising are the anti-angiogenics represented by the family of monoclonal antibodies and small molecule based tyrosine kinase inhibitors (TKIs). The monoclonal antibodies are designed either to bind to the extracellular domains of the overexpressed receptors or to inhibit angiogenic regulators, including bevacizumab (Avastin Ò ) [61] and trastuzumab (Herceptin Ò ) [62] . Multi-TKIs are designed to target the intracellular tyrosine kinase domain of the receptors and these include sunitinib (Sutent Ò ) [63] , sorafenib (Nexavar Ò ) [64] and pazopanib (Votrient Ò ) [65] , with more recent developments in this area contained in a review by Gotink et al. [66] .
Although small molecule VDAs are not specific to tumour vessels, they exploit pathophysiological differences between normal and tumour tissue endothelium to achieve tumour vessel selectivity. Perhaps the best known class of VDAs are the tubulin targeting agents which have both anti-mitotic and anti-vascular effects, leading to inhibition of spindle formation (mitotic arrest) and reduced tumour blood flow, respectively [67] . The earliest tubulin binding agents which demonstrated anti-mitotic and anti-vascular activity included colchicine [68], the vinca alkaloids e.g. vincristine (Oncovin Ò ) [69] and the taxanes e.g. paclitaxel (PTX, Taxol Ò ) [70] ; however these compounds have a very narrow therapeutic window associated with consequent dose limiting toxicities (DLTs) [71, 72] .
The first small molecule VDA that was shown to have anti-vascular effects at doses below the maximum tolerated dose (MTD) was combretastatin A-4 (CA-4) [73] , a tubulin binding agent with structural similarities to colchicine that was isolated from the Cape bushwillow tree, Combretum caffrum [74, 75] . CA-4 treatment has shown to cause extensive tumour vascular damage and necrosis in vivo at relatively non-toxic doses [73] . A more soluble disodium phosphate (CA-4P) prodrug form has been developed. CA-4P is rapidly cleaved by endogenous non-specific phosphatases to release the active CA-4 [76] . Pre-clinical studies in mouse and rat tumour models demonstrated that CA-4P was able to cause rapid tumour vascular shutdown and reduce blood flow at doses well below the MTD, offering a wide therapeutic index [73] , while normal tissue was much less affected [77, 78] . The vascular shutdown induced by CA-4P in tumours is due to the change in shape of newly formed endothelial cells [79] , causing microtubule breakdown and reorganisation in the actin cytoskeleton, resulting in membrane blebbing [80] . CA-4P completed Phase I and II clinical trial evaluation in patients with advanced solid tumours such as anaplastic thyroid cancer and lung cancer, and is undergoing Phase III trials in combination with conventional chemotherapy/radiotherapy against a variety of tumour types [75, [81] [82] [83] [84] .
Anti-angiogenic treatment and vasculature normalisation
An additional rationale for the use of anti-angiogenic therapy suggests that treatment with these agents can result in a more ''normal'' vasculature that is more conducive to the delivery of nutrients and therapeutics. This may be especially advantageous as tumour hypoxia results in tumour cell resistance to radiotherapy or cytotoxic agents and induces genetic instability [85] . Previous studies have shown that anti-angiogenic treatment resulted in vascular normalisation by blocking of VEGF or its receptor VEG-FR2, leading to endothelial cell apoptosis and a reduction in vessel diameter, density and permeability [86] [87] [88] . Subsequently, interstitial fluid pressure decreased and, in some tumours, oxygen tension increased [89, 90] . Taking into consideration that anti-angiogenic drugs are normally combined with other chemotherapeutic agents [91] , it is still unclear whether the effect of these agents occurs as a result of vascular normalisation [92] . A better understanding of the molecular mechanism of vascular normalisation may lead to more efficient anti-cancer therapies as well as for other vascular-related diseases. A more comprehensive review on this subject is presented by Jain [93] .
Combination therapy with VDAs and anti-angiogenics
Single agent administration of VDAs can cause massive central tumour necrosis due to vascular collapse; however a narrow viable rim on the periphery of tumour tissue often remains, allowing tumour cells to repopulate and avoiding complete tumour cell death. A possible explanation for this is that the peripheral tumour cells can obtain oxygen and nutrients from the surrounding non-tumour blood vessels, which are less responsive to VDAs [94, 95] . The tumour periphery is the only tumour region that is easily accessible to therapeutic agents, leading to the suggestion that the optimal clinical use of VDAs would be in combination with other treatments, including cytotoxic chemotherapy/radiotherapy. In this way, the remaining viable rim of the tumour may be eliminated, eventually causing total tumour cell death [95] [96] [97] [98] . Use of current anti-angiogenic treatments alone has provided only a modest survival benefit, thus interest in combining anti-angiogenic drugs with conventional cytotoxic chemotherapies as this has been shown to maximise the effect of therapies. For instance, bevacizumab has been approved in combination with a 5-fluorouracil-based (5-FU) regimen, for first and second-line treatment of patients with metastatic colorectal carcinoma [99] , while a recent Phase I clinical trial showed that treatment with CA-4P, a VDA, in combination with bevacizumab resulted in profound tumour vascular changes [100] .
Hybrid drugs
A relatively new approach which has emerged in the last decade is the design of hybrid based therapies using different modalities. Two or more targeting ligands, which are joined together with a linker to form one individual compound, called a hybrid. Walsh and Bell [101] have discussed the concept of hybrid based approaches for malaria, while Chow and Chan [102] have outlined the concept of hybrid based anti-tumour drug candidates. This concept is based on the premise that drugs in hybrid form may overcome the disadvantages associated with monotherapy or indeed combination chemotherapy in terms of drug resistance, pharmacokinetics and solubility concerns associated with the individual constituents. In addition, the effect of the hybrid drug could be synergistically greater than the free agents. Most importantly, selectivity could be vastly improved because VDAs which have been examined so far have demonstrated a lack of selectivity. In this respect, one component of the hybrid drug could act as a tumour-homing device in order to target specifically tumour vessels while the other component may be the active agent [103, 104] . Other design strategies that can be adopted include presenting both moieties in active form, one component of the hybrid in prodrug form or both moieties in prodrug form, giving an overall pro-prodrug. Frequently, hybrids depend upon specific enzymes or chemical transformation to release their two components as active agents; in this way systemic toxicity may be reduced and drug delivery may be optimised to the target site [105] .
Nevertheless, administration of hybrid based inhibitors may have a reduced effect compared to the combination of single constituents, perhaps because of the increased bulk of the molecule which may decrease penetration to the target site. Combination treatment with individual drugs should be examined at an early stage and then compared to the hybrid in order to observe any potential benefits or drawbacks of the hybrid over the individual components.
Hybrid approaches
A variety of hybrid designs have been proposed and evaluated for use as anti-cancer agents, revealing their benefits in drug delivery as well as their inherent associated complexity. Such designs include hybrids/conjugates with either one or both components aiming to inhibit tumour angiogenesis or disrupt the existing tumour vasculature. Rejniak et al. [106] have published a review on hybrid models of tumour growth emphasising the mathematical modelling approaches that can handle multiple intracellular and extracellular factors, and assist in the design of hybrid molecules.
In this review, an overview of the preclinical evaluation of hybrids/conjugates designed to target tumour angiogenesis and vasculature will include: (1) RGD/NGR-related conjugates, (2) heparin-associated conjugates, (3) tubulin targeting-cytotoxic hybrids, (4) antibody-drug hybrids and (5) toxin-drug hybrids (Fig. 1 ).
RGD/NGR-related hybrids
Targeted delivery of cytotoxic agents to the tumour vasculature may be achieved by the identification of molecular markers that differentiate newly formed capillaries from mature vessels. Integrins are heterodimeric transmembrane proteins that represent a family of over 15 a and 8 b subunits which can heterodimerise to form over 20 combinations. A single ECM ligand could be recognised by different integrin combinations, while others may recognise several different ECM proteins. Integrin-mediated adhesion induces intracellular signalling pathways that modulate cell survival, proliferation and migration [107] . These signals involve phosphorylation of non-receptor tyrosine kinases (such as focal adhesion kinase and Src kinases), inositol lipid synthesis and elevation in intracellular calcium and pH. Consequently, a number of downstream signals are triggered, including activation of the RAS/MAPK pathway [107] . Activated endothelial cells express several types of integrins on their surface during angiogenesis, which regulate critical adhesive interactions with several ECM proteins such as fibronectin, vitronectin, laminin, fibrinogen, von Willebrand factor, collagen types I and IV and denatured collagen. Cell migration, proliferation and differentiation are distinct biological events which are regulated by these adhesive interactions and which are involved in the process of angiogenesis [108] . An interesting expression pattern has been identified by integrin a m b 3 with an exposed RGD sequence on endothelial cells undergoing angiogenesis in tumours, wound healing or inflammatory tissues, and this might be a useful diagnostic or prognostic indicator of tumours [109] [110] [111] [112] .
One of the best known and specific markers is the a m b 3 integrin which mediates the attachment of endothelial cells to sub-matrix proteins such as vitronectin, which forms the capillaries' basement membrane [113] . The a m b 3 integrin is found on the luminal surface of the endothelial cells only during angiogenesis and vascular remodelling [110, 114] , although all endothelial cells use the integrin to attach to the extraluminar sub-matrix. Phage display studies have distinguished a selective ligand sequence RGD which has high affinity for the a m b 3 integrin [115] . The tissue distribution of a m b 3 integrin is limited in adults but it is expressed on a small percentage of activated macrophages, leukocytes and osteoclasts, where it appears to be involved in bone resorption and immune function. The a m b 3 integrin is also expressed in some invasive tumours, such as latestage glioblastomas and metastatic melanomas, leading to the malignant phenotype of the tumour [116] . Previous studies suggested that a m b 3 integrin may serve as an effective diagnostic or prognostic indicator of malignancies.
PTX-RGD conjugate
In order to increase selectivity to tumour blood vessels, different studies have used several chemotherapeutic agents linked to the RGD peptide. Chen et al. designed a dimeric RGD peptide E[c(RGDyK)] 2 , a potent a m -integrin antagonist, as a carrier for PTX in order to specifically target tumour vasculature and breast cancer cells. RGD peptide inhibited cell cycle proliferation by G 0 /G 1 -phase arrest, whereas the PTX-RGD conjugate 1, showed inhibition of cell proliferation mediated by a G 2 /M-phase cell cycle arrest followed by apoptosis, and its activity was comparable to that observed for PTX. The integrin binding affinity of 1 was slightly reduced compared to the unconjugated peptide; however there was specific accumulation [104, 117-121, 127, 128, 142, 150] , APN [104, 133-141, 146, 147] , selectins [161, 168, 171, 173, 175-179, 184, 185] , tubulin [186, 187, 190] , antigens [196-198, 204, 205] , VEGFR [219, 223] and galectin-1 [232] Angiogenesis (2013) 16:503-524 507 of the conjugate in integrin-expressing sites in vivo. The highest tumour uptake of 125 I-labeled PTX-RGD was observed after 2 h post-injection and the best tumour/ background contrast after 4 h post-injection. These results demonstrated the potential of the conjugate to be delivered specifically to integrin-rich sites of the tumour and the vasculature, thereby reducing toxicity and improving selectivity [117] . In another study, PTX was conjugated with a divalent cyclic peptide E-[c(RGDfK) 2 ], which is a novel ligand-based vascular targeting agent that binds to a m b 3 integrin, and showed high uptake in OVCAR-3 xenograft tumours [118] . Promising results were observed in vitro, although the PTX conjugate was inactive in vivo following intravenous (i.v.) administration in an ovarian cancer xenograft model. A possible reason suggested by the authors which could explain the lack of efficacy of the PTX conjugate in vivo, was premature release of PTX into the circulation and thus reduced accumulation of the active drug at the tumour site [119] . Nevertheless, as PTX is a well known anti-cancer agent one might still have expected a small degree of anti-tumour activity. Perhaps a more likely outcome is extensive metabolism of the conjugate to inactive metabolites in vivo (Fig. 2) .
MMAE-HSA-RGD hybrid
The tubulin targeting agent, monomethyl auristatin E (MMAE) was bound via the valine-citrulline linker to human serum albumin (HSA), which is a biocompatible and biodegradable carrier. Conjugation of cRGD peptides to MMAE-HSA was established either by a polyethylene glycol (PEG) linker or a short alkyl linker, in order to promote selectivity to angiogenic endothelial cells. Both conjugates inhibited the proliferation of human umbilical vein endothelial cells (HUVECs) at nM concentrations and displayed excellent tumour homing properties upon i.v. administration in C26 tumour models [120] . It is worth noting that no control compounds such as MMAE were examined in order to better define the conjugates' activity. Furthermore, MMAE prodrug, which recruits tumourassociated protease legumain for its activation, was designed to target cell surface a m b 3 integrin. MMAE conjugate strongly induced cell death of MDA-MB-435 breast cancer cells which are positive for a m b 3 integrin expression. Treatment of tumour bearing mice with 3 mg/kg every 3 days for 17 days resulted in decreased tumour growth and metastasis in 4T1 murine breast cancer, D121 Lewis lung carcinoma and MDA-MB-435 models. These findings suggest that MMAE's activity was enhanced by selective targeting of integrin-rich sites and legumain protease on tumour cells, which otherwise would be too toxic to use for therapeutic applications at the dose evaluated [121] .
sFlt-1 gene-PEI-g-PEG-RGD conjugate
Gene therapy is a different strategy which selectively aims to target tumour vasculature by inhibiting angiogenesis. Several studies have described RGD-mediated gene delivery systems for transferring siRNA [122] or luciferase reporter gene [123] . A study conducted by Kim et al. reported a therapeutic gene encoding Flt-1 (fms-like tyrosine kinase-1) and evaluated its anti-angiogenic activity when conjugated to PEI-g-PEG-RGD (polyethylenimine with a hydrophilic PEG spacer) gene carrier. Flt-1 is a VEGFR which upon activation leads to endothelial cell stimulation, proliferation, migration and capillary tube formation [124] . Soluble Flt-1 (sFlt-1) impairs the action of VEGF. Although the transmembrane and intracellular [117] tyrosine kinase domains are absent, sFlt-1 binds to VEGF with the same affinity and specificity as that of the fulllength receptor [125] . The PEI part of the conjugate could increase the transfection efficiency by avoiding degradation of DNA complexes from endosome or lysosome compartments [126] , and the PEG could decrease the cytotoxicity and increase the solubility of the conjugate. The results of this study showed that the complex of sFlt-1 gene with PEI-g-PEG-RGD conjugate effectively and selectively inhibited endothelial cell proliferation, by blocking the binding of VEGF to the actual Flt-1 receptor [127] .
Further studies evaluated the effect of repeated treatment with the conjugate in vivo which resulted in antitumour activity and an increased survival rate; however the effect was not identified in PEI-g-PEG/pCMVsFlt-1 or PEI-g-PEG-RGD/pCMV-GFP control groups. These findings suggest the use of a non-viral gene carrier to deliver an anti-angiogenic gene at a low continuous dosage, where it is not possible to use other vectors [128] .
Tumour necrosis factor-a associated RGD/NGR conjugates Corti and Ponzoni have described three strategies which use tumour necrosis factor-a (TNF-a) to increase the local concentration of chemotherapeutic agents at the tumour site. TNF-a is an inflammatory cytokine which increases vascular permeability [129] and is cytotoxic to several tumour cell lines. It induces haemorrhagic necrosis in certain solid tumours and has also shown significant antitumour activity in animal models [130, 131] . Despite its success in vivo, the use of TNF-a therapy in the clinic has been limited due to systemic toxicity.
To address this concern, different approaches were introduced, the first one using TNF-a before the administration of chemotherapy in order to increase vascular permeability and enhance the diffusion of the anti-cancer agent into the tumour. The second strategy was based on targeting aminopeptidase N (APN/CD13) present on blood vessels undergoing angiogenesis but not quiescent vessels [132] , by coupling TNF-a to the peptide CNGRC (asparagine-glycine-arginine). The NGR-TNF-a conjugate showed increased leakage of the vasculature in the treated murine lymphomas compared to the controls. Immunohistochemical analysis revealed decreased tumour hypoxia, as well as elevated tumour blood flow, 2 h after treatment. Interestingly, reduction in tumour hypoxia did not lead to additional tumour growth; however the tumour volume decreased within 24 h following conjugate administration [133] . A Phase I clinical study was conducted with the conjugate to determine its DLTs, MTD and its anti-tumour activity in patients, as well as to examine the vascular response determined by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). NGR-TNF-a was well tolerated and the results from DCE-MRI confirmed the anti-vascular effect of the agent. Approximately one-third of the patients experienced stable disease; however no objective responses were observed [134, 135] . A further trial was conducted using NGR-TNF-a as a single agent in hepatocellular carcinoma (HCC) patients and was well tolerated, with only mild to moderate chills reported as side effects. The overall response rate was 7 %, while 22 % of the patients had stabilised disease [136] . Currently, there are several completed and ongoing Phase II clinical trials with the NGR-TNF-a conjugate as a single agent or in combination therapy for the treatment of mesothelioma, colorectal, liver and ovarian cancer [137] [138] [139] . Phase III studies have commenced evaluating its effect in patients with malignant pleural mesothelioma [140] .
The third strategy, worthy of consideration here although not a true hybrid was to examine the biological effects of doxorubicin (DOX)-encapsulated liposomes coupled with the NGR motif. Improved drug uptake by neuroblastoma tumours and enhanced therapeutic efficacy were observed using DOX-encapsulated liposomes homing to tumour vessels [141] . This strategy could prove effective in poorly vascularised tumours where it is harder for therapeutic agents to reach.
In other studies relating to TNF-a, Tandle et al. have reported a hybrid adeno-associated virus phage vector (AAVP) that was used to target tumour endothelium with TNF-a. The AAVP vector targets gene products to tumour vasculature by using the RGD4C peptide. Human melanoma cells were infected with AAVP-TNF-a and resulted in high expression levels of TNF-a, while systemic administration of the RGD-AAVP-TNF-a conjugate to melanoma xenografts produced targeted delivery of the virus to the tumour vasculature; notably, the non-targeted vector was not delivered specifically to tumour vessels. The RGD-AAVP-TNF-a vector enhanced delivery of TNF-a to the tumour vasculature resulting in induction of apoptosis in tumour vasculature and significantly reduced tumour growth, without observable organ toxicity. Therefore, this approach could be useful to target tumour vasculature by delivering anti-cancer agents directly to integrin-expressing tumour angiogenic sites [142] . synthesis and incorporation of its metabolites into DNA or RNA [143, 144] . However, treatment with this agent is associated with various side effects including non-specific toxicity toward normal tissues [145] . Both conjugates exhibited lower cytotoxicity compared to 5-FdUrd, showing selectivity towards APN-positive cells over APN-negative cells [146] . Although these conjugates were not evaluated in vivo, the expectation would be an observable improvement in both efficacy and toxicity associated with these conjugates over 5-FdUrd, especially in tumour types that express high levels of APN.
Platinum-based RGD/NGR conjugates
Platinum ( The Pt(IV)-NGR complexs 3a and 3b were less active than the Pt(IV)-RGD conjugates, but nevertheless showed higher activity compared to the control complexes [104] . The difference in activity of these conjugates could be due to the expression patterns of APN and integrins in the cell lines used (Fig. 3) .
Although not studied directly in a tumour angiogenesis environment, Ndinguri et al. synthesised a Pt-based conjugate, cyclic mPEG-CNGRC-Pt and a dichloro(ethylenediamine)platinum(II) (PtenCl2) based conjugate, cyclic mPEG-CNGRC-Pten. Selective delivery of these conjugates was observed in APN-positive PC-3 cells and these agents exhibited significantly higher activity over untargeted carboplatin. Further analysis on the effects of these conjugates on PC-3 cells was determined using caspase-3 and -7 activation, fluorescence microscopy and DNA fragmentation, which confirmed the induction of apoptosis [147] . As this targeting approach was effective against APN-positive cell lines, one might expect a similar translational effect with these agents against proliferating endothelial cells and indeed angiogenic environments.
Hybrid-based strategies that incorporate a RGD/NGR homing ligand have compromised an active area of recent research in this field. What is presented here is a snapshot of the area. A more comprehensive review of the RGDconjugates has been presented by Temming et al. [148] who concentrate on the structural requirements for RGDpeptides and RGD-mimetics as ligands for a m b 3 , while an additional review by Corti et al. [149] focuses on structural and functional properties of the NGR motif and its applications in anti-angiogenic therapeutics (Table 1) .
Heparin-related hybrids
Heparin is a highly sulphated natural polysaccharide, which is mainly composed of alternating units of sulphated glucuronic acid and glucosamine units. Heparin is well known for its anticoagulant activity, as well as for its interaction with growth factors, including VEGF and bFGF [151, 152] . Heparin treatment was formerly performed in a large number of clinical trials with cancer patients in order to treat venous thrombosis, leading to the suggestion that heparin also prolongs cancer patient survival [153] . Thus, heparin was found to inhibit angiogenesis and tumour progression and also to diminish metastasis by blocking selectin-mediated intercellular interactions [154] [155] [156] , and by regulating various proteolytic enzymes essential for invasion of cancer cells and angiogenesis, through the ECM [153, 157] .
However, due to its high anticoagulant effect which may induce haemorrhage as a side effect [158] , heparin could only be administered at low concentration. Therefore, a number of heparin derivatives have been developed with non anticoagulant activity, while still maintaining their anti-angiogenic effects. A recent clinical trial has shown that low molecular weight heparins (LMWH) may provide an additional advantage in combination with chemotherapeutics, providing an increased tumour uptake and chemoresponsiveness in cancer patients [159] . It was proposed that the optimal anti-angiogenic activity of LMWH fractions varies between 3-and 6-kDa [160] .
In contrast, Folkman et al. [161] have previously established that heparin alone could enhance tumour angiogenesis in the chorioallantoic membrane (CAM) assay. In a further extension of this work, it was noted that when the anti-inflammatory steroid cortisone was added the resultant combination suppressed background inflammation and inhibited angiogenesis, although cortisone a b Fig. 3 RGD and NGR platinum-based conjugates, 2a, 2b and 3a, 3b [104] alone had little or no effect. Several follow-on studies employing heparin as the basis of the scaffold have explored hybrid designs and these are now discussed in detail.
HAH-cortisol hybrid
The most closely related study to the above involved utilising a non anti-coagulating derivative of heparin, namely heparin adipic hydrazide (HAH), which was linked by an acid-labile bond to cortisol (hydrocortisone). Although heparin receptors are present on other cell types, the majority of systemically administered heparin is taken up by vascular endothelial cells, which bind to sulphated polyanion receptors [162] [163] [164] , and by cells of the reticuloendothelial system [165, 166] (possibly due to the vast surface area of these cells which are in contact with the blood). Dividing endothelial cells are more susceptible to heparin's effect as they bind and endocytose tenfold more heparin than non-dividing endothelial cells [167] . In this study, HAH and HAH-cortisol conjugate 4 inhibited DNA synthesis by murine pulmonary capillary endothelial cells (MPCE). The conjugate was more effective than the individual compounds either alone or in combination. HAHcortisol slowed down the healing of wounded MPCE monolayer, and inhibited cell proliferation and migration. Neither the conjugate nor free HAH caused signs of toxicity when administered i.v. to mice at doses of 10 mg/day for 14 days, unlike heparin and cortisol which were lethal at this dose. The anti-tumour effect of the conjugate and free drugs was examined in vivo by daily i.v. administration into animals bearing established subcutaneous (s.c.) Lewis lung carcinomas. Treatment with 4 showed highly significant retardation of tumour growth compared with cortisol alone or in combination with HAH, whereas no reduction in tumour growth was observed with HAH alone [168] .
Heparin-carrying polystyrene conjugate
Heparin-carrying polystyrene (HCPS) has been previously described as a synthetic glycoconjugate that has an amphiphilic structural unit consisting of hydrophilic polysaccharides and hydrophobic polystyrene moieties [169] . This conjugate showed a significantly reduced anticoagulant activity and was able to interact substantially with various heparin-binding growth factors known to stimulate angiogenesis, including FGF-2, VEGF 165 and hepatocyte growth factor (HGF) [170] . The effect of HCPS on cell growth was examined in growth factor-induced human dermal microvascular endothelial cells (HMVEC), and was found to inhibit growth in a dose-dependent manner, even at low concentrations (2 lg/mL). Strong inhibition of tubular formation was noted following 2 lg/mL HCPS treatment of HMVEC seeded on matrigel, while antiinvasive activity and inhibition of cell adhesion was observed in Lewis lung carcinoma (3LL) and B16 mouse melanoma cells treated with 4 lg/mL of HCPS. Treatment with HCPS showed a 40 % reduction of 3LL tumours and 10 % reduction of B16 tumours. Moreover, HCPS treatment reduced the number of CD34-positive vessels in Lewis lung carcinoma tumours and demonstrated antimetastatic activity on both cancer cell lines, suggesting that this conjugate may be beneficial in a clinical setting [170] . The in vivo data obtained suggests there is merit in the use of this conjugate in the treatment of Lewis lung carcinoma. Heparin-DOCA conjugate
In a separate study, a chemically modified heparin derivative, heparin-deoxycholic acid (HD) was designed by covalently coupling N-deoxycholylethylenediamine (DOCA-NH 2 ) to heparin to serve as a hydrophobic segment [171] . The resultant hybrid, coined a macromolecular aggregate, was shown to localise to tumour sites by the enhanced permeability and retention effect (EPR) [172] . The amide conjugate 5 was found to exhibit low anticoagulant activity and to form self-assembled nanoparticles in aqueous condition. During BrdU incorporation assays, 5 inhibited HUVECs and SCC proliferation. The antiangiogenic activity of 5 and heparin was examined using HUVECs layered onto matrigel-coated plates. The inhibitory effect of 100 lg/mL of 5 was more evident than heparin, as HUVECs gradually lost their intercellular contact. In order to test the ability of HD to inhibit bFGFinduced angiogenesis the matrigel plug assay was performed, where mice were injected s.c. with matrigel containing either bFGF, heparin or 5. After 10 days, the animals were sacrificed and matrigel plugs were excised, fixed and stained with either hematoxylin and eosin (H&E) or CD31 antibody (microvessel staining). Matrigel plugs' haemoglobin content was reduced up to 82 % by 5, indicating that HD effectively inhibited angiogenesis; however, neither heparin nor bFGF alone demonstrated any activity. The effect of 5 on the signal pathways (namely phosphorylation of FGFR, extracellular signal regulated kinase (ERK) and p38 MAPK) induced by bFGF was investigated. HUVECs were incubated with or without 5 in the presence or absence of bFGF and the phosphorylation of FGFR, ERK and p38 MAPK was analysed. The results suggested that 5 interacts with bFGF receptors and interferes with signalling pathways involving FGFR, ERK and p38 MAPK phosphorylation, thus suggesting a possible mechanisms by which 5 inhibits cell proliferation and angiogenesis. The results from the in vivo experiments showed that 5 inhibited tumour growth in tumour bearing mice in a dosedependent manner [173] . The process of angiogenesis is complex and difficult to regulate; however these findings are encouraging because 5 demonstrated interaction with not only one but several signalling pathways, thus making it easier to modulate angiogenesis (Fig. 4 ).
An extension of this study involved loading DOX onto the amphiphilic HD conjugate in order to evaluate the use of this formulation in sustained drug release studies. DOXloaded heparin nanoparticles (DHN) showed lower toxicity than free DOX. HD conjugate, DOX and DHN activity was evaluated in tumour bearing mice and the reduction in tumour volume was 43, 56 and 74 % respectively, confirming that DHN is more effective than the free agents and might provide a novel therapy for SCC [174] . The fact that DHN treatment had shown a safer toxicological profile than free DOX reveals an additional advantage for this type of therapy.
LMWH-DOCA conjugate
Another conjugate, LHD, was synthesised, by conjugating the carboxylic groups of LMWH to the carboxylic group of DOCA. Similar results were obtained when the antiangiogenic effect of LHD and LMWH was examined in the capillary tube assay. The CAM assay was used to investigate the interaction between LMWH, LHD and bFGF. Although the effect of LMWH appeared smaller than LHD, the difference was not significant. The matrigel plug assay was performed and the haemoglobin contents of plugs from animals treated with LHD and LMWH versus (vs) untreated controls were 34.0 ± 4.8 and 102.3 ± 7.2 %, respectively, suggesting that LHD reduced the haemoglobin content, whereas LMWH had no significant effect.
Microvessel density was also reduced by LHD treatment, but not by LMWH. The size of the tumours in SCC7 murine xenograft models was diminished with LHD treatment and the number of tumour microvessels decreased in a dose-dependent manner. Combination therapy of LHD and DOX enhanced the anti-tumour effect in vivo compared to individual components, which suggests that this treatment may be a useful therapy for SCC [175, 176] . Additional studies revealed that LHD oral administration attenuated metastasis in B16F10 murine melanoma or A549 human lung carcinoma cells [177] . Moreover, LHD conjugates with further reduced anticoagulant activity were synthesised by controlling the DOCA coupling ratio, and showed inhibition of angiogenesis and tumour growth in SCC7 and A549 xenografts [178] .
Additionally, a LMWH-taurocholate conjugate (LHT7) was synthesised and showed to have low anticoagulant activity, bind to VEGF 165 strongly (K d value: (3.21 ± 0.04) 9 10 -7 M) than LMWH (K d value: (1.86 ± 0.10) 9 10 -5 M) and inhibit VEGF-dependent KDR phosphorylation. When LHT7 was evaluated in the matrigel plug assay it showed a strong anti-angiogenic effect. In vivo efficacy studies resulted in a significant reduction in SCC7 tumour growth and increased survival rate [179] .
Folate-HL conjugate
Yu et al. have designed low anticoagulant heparin amphiphiles: heparin-lithocholic acid conjugate (HL) and folateconjugated HL (FHL, 6), [96] . Folate receptors are overexpressed in various cancer types, including ovarian, endometrial, breast and colorectal cancers [180] [181] [182] [183] . They have also been identified as markers of specific tumours for diagnostic and therapeutic purposes. In this study, 100 lg/ mL of unfractionated heparin (UFH), HL and 6 were examined in the in vivo matrigel plug assay and the results showed that HL and 6 significantly inhibited plugs' vascularisation, where the haemoglobin content was reduced to 29 and 43 %, respectively. The effect of UFH was less than that of HL and 6, although still significant compared to the positive control. Cytotoxicity of the conjugates was evaluated in KB cervical adenocarcinoma cells using the MTT assay and showed that 6 reduced the viability of cells to 25 % following 24 h incubation; HL had no effect on cell viability. FHL-treated cells induced sub-G 1 phase accumulation (an indication of apoptosis) and induced a high amount of apoptotic cells after annexin V/propidium iodide (PI) staining, whereas UFH and HL had no effect. Cellular internalisation of HL and 6 in KB cells was investigated and 6 showed higher cellular uptake than HL indicating that folate conjugation provided the ability for cellular endocytosis. In vivo results revealed that both administered HL and 6 had similar anti-angiogenic activity and inhibitory effect on tumour growth; however FHL induced higher levels of apoptosis on tumour tissues [184] . The anti-angiogenic activity along with the apoptotic effects on cancer cells may provide an additional advantage for the evaluation of 6 in preclinical and clinical settings.
cRGD-HL conjugate
In a similar study, the investigators designed a cRGD-HL conjugate 7. Adhesion studies were performed using HUVECs. The addition of heparin, cRGDyK, HL and 7 decreased cell adhesion by 39.1, 45.0, 54.2 and 65.6 %, respectively. Additionally, the effect on cell migration was tested and was effectively reduced by 27.0 % (heparin), 47.8 % (cRGDyK), 72.1 % (HL), and 82.8 % (7). The inhibition of capillary tube formation was most profound in 7-treated cells, and where receptor binding studies have shown that 7 exhibited higher binding affinity for purified a m b 3 integrin, over cRGDyK. In the matrigel plug assay, 7 significantly inhibited bFGF-induced angiogenesis and tumour growth activity with superior anti-tumour effect for 7, compared to heparin and cRGDyK. The enhanced activity of the conjugate was suggested to be due to the anti-angiogenic characteristics of the heparin derivative (mediated through bFGF inhibition) and the additional effect from the integrin-mediated interaction of the functionalised heparin derivative [185] .
In summary, most of the heparin-related conjugates demonstrated significant differences in activity from their single components and co-administration of the individual components in a 1:1 ratio of the two. However, it is important that heparin analogues are properly examined for anticoagulant activity at an early stage, as well as at a more advanced in vivo setting, due to the fact that heparin conjugates could be metabolised into toxic analogues which may induce internal haemorrhage ( Fig. 5 ; Table 2 ).
Tubulin targeting cytotoxic hybrids
Tubulin targeting cytotoxic hybrids have been designed to have one component which targets tubulin, either for antiangiogenic, anti-vascular or anti-tumour purposes, and another which serves as a cytotoxic agent. Early studies have involved linking a microtubule-targeting moiety with another anti-cancer agent which has a different target. For instance, Nakagawa-Goto et al. have designed different taxoid conjugates by linking various anti-cancer agents including glycyrrhetinic acid, colchicine, epipodophyllotoxin and camptothecin (CPT). PTX-CPT conjugates exhibited anti-angiogenic properties, as well as reduced inhibitory activity against normal human lung fibroblasts. Also, the PTX-CPT conjugates demonstrated higher anticancer activity against PC-3 and LN-CAP prostate cancer cells than PTX itself [186] . Another approach which has been exploited is the development of hybrids that link two tubulin targeting agents. For example, an admantane-based taxane-colchicine conjugate exhibited superior cytotoxicity against A549 adenocarcinomic human alveolar basal epithelial cells [187] . An additional colchicine-based hybrid was synthesised by its conjugation with caulerpenyne, a toxin isolated from the marine alga C. taxifolia [188] , which exhibited inhibition of tubulin polymerisation and proliferation of SK-N-SH neuroblastoma cells [189] . The activity of the colchicine-caulerpenyne hybrid was disappointing against tubulin polymerisation, with an IC 50 value [100 lM. High concentration (10 lM) of the hybrid was required to inhibit more than 50 % of the capillary network formation [190] . The fact that the hybrid demonstrated [184] and cRGD-heparinlithocholic acid (cRGD-HL) conjugate, 7 [185] poor tubulin polymerisation activity, but still inhibited the capillary tube formation at 10 lM may indicate that this was as a result of possible slow hydrolysis into different components. A re-evaluation on the concept of tubulin targeting agents in hybrid drugs is contained in a review by Breen and Walsh [105] .
Antibody-drug hybrids
Despite the success of monoclonal antibodies in the clinic, naked antibodies targeting tumour associated antigens are mostly administered in combination with chemotherapy [191] . A relatively new approach is the development of antibody-drug conjugates which allows for the combination of the selectivity of monoclonal antibodies with the potency of cytotoxic drugs. This strategy aims to minimise systemic toxicity and to increase therapeutic efficacy. In fact, several studies demonstrated that antibody-drug conjugates enhanced the anti-tumour effect of naked antibodies and showed reduced systemic toxicity associated with the cytotoxic drugs conjugated to the antibody [192, 193] .
PTX-cetuximab hybrid
As outlined above, tubulin targeting agents in particular have shown pronounced anti-vascular effects, but in certain situations have dose-limiting toxicities. To address this, antibody-drug conjugates have been synthesised which incorporate tubulin binding agents into the conjugate. This area has been extensively reviewed by Stack and Walsh [194] . For example, PTX has been used for such studies where it has been conjugated to a monoclonal antibody: cetuximab (a monoclonal antibody targeting EGFR). The in vitro cytotoxicity results indicated enhancement of the cytocidal effect of PTX as compared to that of the free drug, the intact antibody, and a physical mixture of the two. The in vivo anti-tumour activity of the conjugate was similar to that of cetuximab alone, which may be due to either a relatively low dose of the antibodydelivered drug (346 lg/kg) or extensive release of the conjugate into the circulation [195] . Although this conjugate was not directly investigated in an angiogenic setting, one would expect a direct anti-vascular effect from this hybrid, as the receptor involved is highly expressed on proliferating endothelial cells.
Trastuzumab-DM1 hybrid
The monoclonal antibody trastuzumab (which interferes with the HER2 receptor) has been conjugated with maytansinoid (DM1), a microtubule depolymerising agent. The resulting conjugate trastuzumab-DM1 (T-DM1) was designed to deliver DM1 into the HER2 over-expressing cells via receptor mediated endocytosis. In this way, inactivation of the HER2 receptors should result in inhibition of signalling cascades, including PI3 K/AKT and MAPK pathways, which are associated with cell proliferation and angiogenesis. In addition, disruption of tumour vasculature and angiogenesis may also be mediated by the action of the tubulin binding component, DM1. T-DM1 conjugate has shown activity in both in vitro and in vivo models of trastuzumab-resistant breast cancer [196] . It has also shown remarkable activity in Phase I and II clinical trials in patients with trastuzumab-resistant HER2-expressing breast cancer [197, 198] .
Prostate specific membrane antigen (PSMA) conjugates
Further studies with antibody conjugates were carried out using an antibody against PSMA. PSMA is a membrane glycoprotein that is predominantly expressed in the prostate and in the neovasculature of various solid tumours, indicating its relevance as a target of the tumour vasculature [199, 200] . It is also present in the serum of prostate cancer patients [201, 202] . The anti-PSMA antibody was conjugated to the tubulin binding agent monomethyl auristatin E (MMAE), which is a synthetic analogue of dolastatin 10 [203] . The anti-PSMA-MMAE hybrid demonstrated selectivity towards PSMA-expressing cell lines and showed high in vivo activity in prostate tumour xenografts following an initial course of docetaxel therapy [204] . An additional example includes the anti-PSMA antibody huJ591, which was conjugated to various toxins and radionucleotides. The anti-PSMA conjugate showed promising potential for prostate cancer therapy and other solid tumours [205] .
Cytokine fusion chimeras
Immunotherapeutics not only include conjugation to cytotoxic drugs but also fusion to cytokines (cytokine fusion chimeras). A monoclonal antibody, L19, was developed targeting a tumour specific splice form of fibronectin, which is selectively expressed on the tumour vasculature within a variety of tumours [206] . In addition, several derivatives of L19 antibody were generated and showed preclinical and clinical efficacy by specifically targeting the tumour vasculature [207] [208] [209] [210] . Furthermore, two high affinity human antibodies, G11 and F16, were shown to bind to the large isoform of tenascin-C, a type of ECM glycoprotein expressed in different types of connective tissues, with a prominent perivascular pattern [211] . The activity of G11 and F16 antibodies was evaluated in a U87 glioblastoma xenograft model and showed a significant anti-tumour effect, by demonstrating accumulation at the tumour site but not in other organs [212] . Gerber et al. [213] have summarised the recent developments of antibody-drug conjugates which target the tumour vasculature and outlined future directions in that field by indicating some potential targets.
Toxin-drug hybrids
Similarly to the monoclonal antibodies, immunotoxins have previously been designed by using chemical [214] or molecular [215] approaches and have proved effective against lymphomas and leukaemias [216] . However, disappointing clinical results were observed in carcinoma and melanoma patients, most probably because these conjugates permeate poorly and unevenly into solid tumours [215, 217] . Thus, designing toxin conjugates which selectively target the tumour microenvironment and in particular the tumour vasculature was of paramount importance. In parallel with this initiative, studies have been performed where toxins have been incorporated into hybrid designs.
VEGF-toxin hybrids
A different strategy to target the tumour vasculature directly was introduced by Ramakrishnan et al. [218] who reported that a toxin polypeptide linked to the VEGF 165 isoform can be used to target VEGF receptors and to inhibit the proliferation of endothelial cells. In addition, the VEGF 165 -toxin conjugate demonstrated inhibition of angiogenesis in the chick CAM assay and reduced the tumour growth of ovarian tumour xenografts [219] .
Once it had been identified that VEGF 165 binds to the neuropilin-1 receptor (NP-1) expressed on endothelial and tumour cells, as well as in adult heart and placenta [220, 221] , a different VEGF isoform, VEGF 121 , was used for conjugation with toxins, which binds to VEGFR-2 but not NP-1 [222] . A truncated form of diphtheria toxin (DT385) which contains the catalytic and the translocation domain of diphtheria toxin but lacks the innate receptor-binding domain was employed as the effector molecule. In order to facilitate chemical conjugation with VEGF 121 , DT385 was genetically modified to incorporate a cysteine residue at the carboxyl terminus. The VEGF 121 -DT385 conjugate demonstrated selective inhibition of endothelial cell proliferation, angiogenesis and tumour growth in vivo, without apparent toxicity [223] .
Irofulven-anginex hybrid
Irofulven (MGI-114; 6-hydroxymethylacylfulvene) is a leading member of the acylfulvenes, which are a semisynthetic class of compounds derived from illudin S, a toxin produced by the Omphalotus illudens mushroom, which has demonstrated in vitro and in vivo anti-tumour activities. Irofulven has shown clinical activity against a variety of cancers, alone or in combination with other chemotherapeutic agents [224] . However, DLTs were observed including myelosuppresion, neutropenia, thrombocytopenia, nausea, vomiting and fatigue [225, 226] . In order to reduce the systemic toxicity and maintain (or even improve) the clinical efficacy, irofulven was conjugated to anginex [227, 228] , an anti-angiogenic agent which targets galectin-1 [229] (a cell surface glycan binding protein which is highly up-regulated in tumour-activated endothelial cells) [230, 231] . The irofulven-anginex conjugate demonstrated superior activity to that of equivalent doses of either compound alone, in an ovarian tumour xenograft model, and selectively targeted the tumour vasculature by inhibition of tumour angiogenesis. Interestingly, the conjugate has not shown apparent systemic toxicity unlike irofulven [232] (Table 3) .
Conclusions
The development of cancer is a complex process which depends on both intrinsic factors (i.e. gene expression, genetic mutation, cell adaptability) and on extrinsic signals sensed by the cell microenvironment (e.g. nutrient and metabolite gradient). Wherever there are solid tumours, there will be blood vessels to support the tumour growth. Although the majority of the approved anti-cancer agents so far are designed to target tumour cells directly, recent approaches aim to design drugs that indirectly kill cancer cells by targeting the tumour microenvironment and more specifically the tumour vasculature. The body of evidence introduced in this review indicates that the concept of hybrid/conjugate design is laudable and further research is encouraging. Emphasis should be placed on addressing the more aggressive, potentially metastatic and resistant cell lines, as well as on the poorly vascularised tumours where it is hard for therapeutic agents to reach. Furthermore, it is essential that both of the hybrid's components are evaluated individually and in physical combination at different ratios (e.g. 1:1, 1:2), in order to examine their activity and to reveal any advantages or disadvantages over the hybrid treatment. Several papers cited in this review have not established the effectiveness of the combination therapy and thus have not directly proven that the hybrid is more beneficial. The choice of the linker group should be carefully considered with regard to cleavability and also the possibility of metabolites generation in vivo (which metabolites' could mask the effect of the active component). It is also important to take into consideration the fact that the hybrid may terminate in a physiological Admantane-based taxane Colchicine Hybrid exhibited superior cytotoxicity against A549 adenocarcinomic human alveolar basal epithelial cells [187] Caulerpenyne Colchicine Disappointing activity of hybrid against tubulin polymerisation with IC 50 value [100 lM, whereas 50 lM was required to inhibit more than 50 % of the formation of capillary network [190] Antibody-drug hybrids PTX Cetuximab Enhanced cytocidal effect of PTX compared to that of the free drug, the intact antibody, and their 1:1 combination. Hybrid showed similar in vivo anti-tumour activity to that of cetuximab alone [195] DM1 Trastuzumab Demonstrated activity in in vitro and in vivo models and Phase I and II clinical trials in patients with trastuzumab-resistant breast cancer [196] [197] [198] MMAE Anti-PSMA Hybrid showed selectivity towards PSMA-expressing cell lines and high in vivo activity in prostate tumour xenografts [204, 205] Toxin-drug hybrids DT385 toxin VEGF 165 Hybrid displayed inhibition of angiogenesis in the CAM assay and reduced the tumour growth of ovarian tumour xenografts [219] DT385 toxin VEGF 121 Hybrid showed selective inhibition of endothelial cell proliferation, angiogenesis and tumour growth in vivo, without apparent toxicity [223] Irofulven Anginex Conjugate demonstrated superior activity to that of 1:1 combination of single agents, in an ovarian tumour xenograft model, and selectively targeted the tumour vasculature [232] Angiogenesis (2013) 16:503-524 517 environment. Conjugates that specifically aim to target cells over-expressing an angiogenic marker have also demonstrated activity and selectivity to tumour vasculature. However, the choice of the marker has to be cautiously considered and the expression pattern in normal and tumour tissue should be established. As most FDA-approved anti-angiogenic agents are multi-targeted inhibitors of angiogenesis, such as sunitinib and sorafenib, more attention should be paid to the discovery of new compounds that possess dual or multiinhibitory effect. However, resistance to such treatments is a common setback which can occur by a new mutation or by receptor down-regulation. In certain clinical trials, it is crucial to establish selection criteria (e.g. EGFR overexpression) for the participants prior to the initiation of the study, which may result in a successful treatment outcome; although this could be less cost-and time-effective.
In conclusion, the body of data generated to date is encouraging and warrants further detailed studies into the development of novel hybrids targeting tumour angiogenesis/vasculature.
